BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
AssigneeAbbott Laboratories
InventorsAgim Beshiri, Gillian Murtagh, Chris Watson, Eoin O'Connell, James O'Reilly, Stephanie James, Joe Gallagher, Mark Ledwidge, Ken McDonald
Life of this patent
Estimating the term…
Abstract
The invention provides methods of detecting a natriuretic protein, a troponin, and galectin-3 in samples from subjects in order to determine risk of developing new onset heart failure with preserved ejection fraction (HFpEF).
Claims14
A method of detecting a natriuretic peptide, a troponin, and galectin-3 in a sample obtained from a subject, which method comprises:
- (a) obtaining a sample from the subject,
- (b) detecting whether a natriuretic peptide, a troponin, and galectin-3 are present in the sample by contacting the sample with (i) an antibody that specifically binds to the natriuretic peptide, (ii) an antibody that specifically binds to the troponin, and (iii) an antibody that specifically binds to galectin-3.
A method of determining the risk of a subject developing new onset heart failure with preserved ejection fraction (HFpEF), which method comprises:
- (a) obtaining a sample from a subject, (b) contacting the sample with (i) an antibody that specifically binds to a natriuretic peptide, (ii) an antibody that specifically binds to a troponin, and (iii) an antibody that specifically binds to galectin-3,
- (c) detecting binding of the antibodies of (i), (ii), and (iii) of step (b) to a natriuretic peptide, a troponin, and galectin-3, respectively,
- (d) quantifying the amounts of the natriuretic peptide, the troponin, and galectin-3 in the sample, wherein increased levels of the natriuretic peptide, the troponin, and galectin-3 in the sample as compared to normal levels of the natriuretic peptide, the troponin, and galectin-3 indicate an increased risk of the subject developing HFpEF.
A method of treating or monitoring a subject at risk of having heart failure with preserved ejection fraction (HFpEF), which method comprises:
- (a) obtaining a sample from a subject,
- (b) contacting the sample with (i) an antibody that specifically binds to a natriuretic peptide, (ii) an antibody that specifically binds to a troponin, and (iii) an antibody that specifically binds to galectin-3,
- (c) detecting binding of the antibodies of (i), (ii), and (iii) of step (b) to a natriuretic peptide, a troponin, and galectin-3, respectively,
- (d) quantifying the amounts of the natriuretic peptide, the troponin, and galectin-3 in the sample, and
- (e) administering a HFpEF treatment regimen or a HFpEF monitoring regimen to the subject if the natriuretic peptide, the troponin, and galectin-3 levels are higher in the sample as compared to the natriuretic peptide, the troponin, and galectin-3 levels in a control.
Dependencies are inferred from the claim text.